Responsibility reports
We report on a wide range of data in our Responsible Business Report and provide additional ratings and disclosures below.
Latest reports
The Responsible Business Report includes our performance across our six priority areas, and includes data for current and previous years. Within the Responsible Business section of our Annual Report, we provide a summary and highlights of our progress in 2025.

Our position on
Learn more about our views and our practices across a range of access, R&D, intellectual property, health security and environment issues here.
Responsibility reports archive
Search our archive of responsible business reports and resources dating back to 2002.
Responsible business ratings
We regularly review our responsible business ratings to ensure the external benchmarks listed remain high quality, appropriate and relevant to stakeholders. Last updated July 2026.
External benchmarking | Current rating | Previous rating | Comments |
|---|---|---|---|
Access to Medicines Index | 3.72 | 4.06 | Second in the Index, updated bi-annually, current results from November 2024. Scores range from 1 to 5, with 5 being the highest (best) score |
Antimicrobial Resistance Benchmark | 77% | 84% | Led the benchmark since its inception in 2018; Current ranking updated March 2026 |
CDP Climate Change | A | A | Updated annually, current score updated December 2025 |
CDP Water Security | A | A | Updated annually, current score updated December 2025 |
CDP Supplier engagement rating | Leader | Leader | Updated annually, current score updated May 2026 |
Sustainalytics | Low risk | Low risk | 2nd percentile in pharma subindustry group. Current rating as at July 2026 |
ISS Corporate Rating | B+ | B+ | Ranked 1st in our peer group. Latest profile update May 2026 |
FTSE4Good | Member | Member | Member since 2004, latest review in July 2026 |


